

BOULDER - Array BioPharma Inc. announced positive results in its phase 2 acute inflammatory dental pain study involving one of the Boulder-based company's painkillers.

Array's drug, ARRY-797, is a small molecule p38 inhibitor that helps control pain after dental surgery.

The randomized study involved 253 patients with postsurgical pain who were given ARRY-797 a placebo or celecoxib (a painkiller often branded as Celebrex). In the study, Array's drug significantly reduced pain over a six-hour timeframe post dose.

"These results, together with our multiple-dose, 14-day trial in healthy volunteers, confirm that ARRY-797 is well-tolerated at doses that provide acute analgesic benefit and systemic anti-inflammatory activity," Kevin Koch, Array's president and chief scientific officer, said in a press release.

Study participants reported similar side effects to ARRY-797 as reported with the other study groups. No serious adverse effects were reported.